Skip to the guide
EXACT 41

Mitochondrial research / EDUCATIONAL GUIDE

SS-31

SS-31 10 mg box packaging mockup
Packaging mockup
10 mg€39.90

Research aims, observed effects
and the limits of the evidence.

Specific approved medicine existsSources checked 6 September 2026

THE IDEA IN EVERYDAY TERMS

Muscle function in mitochondrial disease

SS-31, also called elamipretide, targets cardiolipin, a lipid in mitochondrial membranes. Mitochondria help cells produce usable energy. The research question is whether targeting this part of the cell can improve function in a disease involving mitochondria, rather than simply making anyone feel more energetic.

Read the background ↗

Small human trial; specific medicine approved

What has actually been shown?

Forzinity, an approved elamipretide medicine, is indicated to improve muscle strength in people with Barth syndrome weighing at least 30 kg. Strength improvements appeared during a longer open-label study period; a significant improvement was not shown in the initial randomized period. Its accelerated approval requires confirmatory evidence. This does not establish general anti-aging or fitness benefits.

Read the evidence ↗

01 / OVERVIEW

What is SS-31?

SS-31 is also known as elamipretide. Its approved formulation, Forzinity, is a mitochondrial cardiolipin binder. [1]

02 / RESEARCH AIMS

Why it is studied.

Clinical development has examined mitochondrial disease. FDA granted accelerated approval to Forzinity in 2025 to improve muscle strength in people with Barth syndrome weighing at least 30 kg. [1]

03 / RESEARCH MAP

Following the research question.

Elamipretide binds cardiolipin, a lipid associated with mitochondrial membranes. The approved medicine targets a specific disease context; this does not validate general energy or anti-aging claims. [1]

SS-31 research map: Elamipretide; Cardiolipin binding; Barth syndromeRESEARCH MAP / SS-3101Elamipretide02Cardiolipin binding03Barth syndrome
Conceptual research map, not a molecular structure or a proven chain of clinical effects. [1]

04 / OBSERVED EFFECTS

What the evidence shows.

The FDA review describes a small clinical programme in Barth syndrome. Accelerated approval requires further confirmation of clinical benefit. [1]

Study context

Small human programme

Key distinction

Accelerated approval

Uncertainty

Confirmatory evidence needed

A selected-source overview, not a systematic review. Research findings are not verified effects of an independently supplied sample.

05 / SAFETY AND LIMITATIONS

Risks belong beside the findings.

Reported risks include injection-site reactions and allergic reactions, sometimes serious. [1]

Approval applies to Forzinity and its labelled population, not every substance labelled SS-31 or to general wellness use.

06 / REFERENCES

Go to the source.

  1. FDA — Forzinity drug trials snapshot ↗

    Official approval, evidence and safety summary.